Zimmer Biomet Director Devdatt Kurdikar Accrues Phantom Stock Units Under Deferred Compensation Plan

Transaction Overview

On September 30, 2026, Devdatt Kurdikar, a member of the Board of Directors at Zimmer Biomet Holdings, Inc. ($ZBH), acquired 173.901 Phantom Stock Units. The filing was submitted to the SEC on Form 4 on October 2, 2026.

Filing Details

• Security: Phantom Stock Units (convertible into Common Stock on a 1-for-1 basis)
• Transaction Code: 'A' (Grant, award, or other acquisition pursuant to Rule 16b-3(d))
• Transaction Price: $0.00 per share (conversion/exercise reference price reported as $89.85)
• Shares Acquired: 173.901 units
• Resulting Ownership: 3,171.359 phantom stock units held directly
• Settlement Terms: Units settle in shares of Zimmer Biomet common stock within 60 days following the cessation of board service.

Significance Assessment

This transaction carries Low trading significance. The acquisition represents routine director compensation credited under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors rather than an open-market purchase or discretionary sale reflecting sentiment on the company's operational trajectory.